American Health Packaging Metoclopramide 5 mg Recall D-0042-2027 Case Study

Why this case matters

Recall D-0042-2027, involving Metoclopramide Tablets, USP, 5 mg distributed by American Health Packaging, belongs to a category of pharmaceutical event that is routine in volume and awkward in analysis. The stated defect is a mix-up during manufacturing rather than a contamination, a potency failure or a labeling error: the recall entry describes a problem with foreign tablets or capsules appearing in the finished product. That distinction shapes everything that follows, because a stray tablet in a bottle of a 5 mg prescription medicine raises questions of identity, of lot integrity and of whether any individual patient could have been harmed, and none of those questions are answered by the short public entry.

The case also serves as a useful illustration of where the public record ends and the legal record would have to begin. A firm-initiated Class II recall is an administrative action. It is not a finding of negligence, not an admission of liability and not an adjudication of anyone’s rights. Readers who encounter a recall number and a carton count may reasonably infer that a settlement or a court case exists somewhere behind the notice. Often there is none, and sometimes there is one that has nothing to do with the public data. Distinguishing those possibilities is the practical value of looking at the record carefully.

CollectiveClaim.us has already reported the core facts of the recall. What follows is a second look, less at what happened and more at what the documents supporting the recall actually establish, what they leave open, and how a legal claim arising from a manufacturing mix-up of this kind would ordinarily be assessed.

The official record

The recall is presented in the supplied documents as an ongoing Class II event, with the summary identifying American Health Packaging as the recalling firm, naming Metoclopramide Tablets, USP, 5 mg, and stating a quantity of 5,363 cartons. The stated reason is foreign tablets or capsules. The status is recorded as ongoing as of October 2026.

The underlying enforcement extract supplied for this analysis is a general openFDA results page rather than a record-specific query. It returns a set of terminated recalls from unrelated firms and products, and its own metadata states that results should be assumed to be unvalidated and not relied upon for medical decisions. The snapshot carries a last-updated date in October 2026. Nothing in that page describes American Health Packaging, metoclopramide, D-0042-2027 or the 5,363-carton figure.

The remaining documents are equally general. Two of them are landing pages for the FDA drug approval databases, each carrying the same standard navigation and description text about what those databases contain, and each noting that they do not include applications or supplements approved by the Center for Biologics Evaluation and Research. One is a Federal Register agency page listing recent FDA rulemaking, including a final rule on salt substitutes published in October 2026. One is a truncated drug adverse-event extract, one a truncated National Drug Code extract, and one a drug labeling extract describing entirely unrelated products. None of them mentions this recall, this product or this firm.

That gap is the central analytical point. The publication’s summary is the only supplied source that describes the recall itself. The regulatory artifacts that accompany most case studies in this series (the enforcement record, the classification date, the termination date, the distribution pattern) are not present here in usable form.

What the documents establish

Reading the record strictly, the following can be said. A recall exists under the identifier D-0042-2027. The recalling firm is American Health Packaging. The product is Metoclopramide Tablets, USP, 5 mg. The stated reason is foreign tablets or capsules. The stated quantity is 5,363 cartons. The classification is Class II. The recall was ongoing as of October 2026.

The documents do not establish several things that a legal analysis would ordinarily require. They do not state the recall initiation date, the center classification date, the report date or any termination date. They do not state the distribution pattern, the number of lots affected, the code information for those lots, or whether the firm notified customers by letter, by press release or by another method. They do not state whether the recall was voluntary or mandated. They do not identify a manufacturing site, a repackager relationship or the source of the foreign tablets. They do not state whether any adverse event, injury or illness was reported in connection with the affected cartons.

They also do not describe any litigation. No court, docket number, plaintiff group, motion, settlement, verdict or regulatory enforcement proceeding appears anywhere in the supplied material. The record as provided does not establish that any claim has been filed, and it does not establish that none has. The most accurate statement is that the documents are silent on litigation.

The quantity figure deserves separate attention. The summary describes 5,363 cartons as the recalled quantity. Cartons are a packaging unit, not a tablet count, and the documents do not convert one to the other or state how many tablets were in each carton. Any attempt to derive an exposed-patient population from that figure would be an inference, not a reading of the record, and the documents supply nothing else from which such a population could be calculated.

How a claim of this kind is assessed

A recall of this type, if it produced litigation at all, would most likely be framed in product liability terms. The analytical questions would be familiar to anyone who follows pharmaceutical cases, even though the answers here are not in the record.

The first question is defect. A foreign tablet in a sealed bottle of a specified strength supports an argument that the product departed from its intended design or from the manufacturing specification, which is the classic form of a manufacturing defect. That is a different theory from a design defect or a failure-to-warn theory, and it requires different evidence. It also requires identifying the foreign tablet, which the documents do not do.

The second question is causation. A manufacturing mix-up creates a genuine issue of proof that contamination cases often avoid: an unexpected tablet may be pharmacologically active and may be an entirely different drug. Establishing injury from such an exposure requires evidence linking a specific patient’s ingestion to a specific affected lot, typically through pharmacy dispensing records, lot numbers and clinical records. The documents supply no lot information and no adverse-event information, so this element cannot be evaluated from them.

The third question is scale. Recall classes are assigned according to the probability that a defective product will cause serious adverse health consequences or death, and a Class II designation sits in the middle of that scale. A classification is a regulatory judgment about exposure and potential harm. It is not a medical finding about any individual and it is not a liability determination.

The fourth question is procedural posture. A firm-initiated recall of the sort described here is a regulatory action. Standing to sue, the available causes of action, the applicable limitations periods and the treatment of economic-loss-only claims all vary by state and by the facts. A recall notice on its own does not establish any of them, and reading it as an admission of fault would overstate what an administrative classification means.

What to check before relying on any figure

The 5,363-carton figure and the October 2026 status are the two most quotable elements in the record, and both should be handled with care.

On quantity, the figure as supplied is a carton count tied to a summary that has not been corroborated by the enforcement extract provided. It should be treated as reported rather than confirmed. It should not be described as a patient count, a tablet count or a dose count, none of which the documents provide. Nor should it be presented as a measure of harm.

On status, “ongoing as of October 2026” is a point-in-time statement, not a permanent condition. Recalls move between statuses. The supplied extract demonstrates that plainly: the unrelated entries it contains carry termination dates years after their report dates, and one carries an initiation date in 2021 with a termination in 2023. A recall described as ongoing in one month may be recorded as terminated in a later snapshot, and a reader relying on the earlier description would be working from outdated information.

On outcomes, the documents state no compensation figure, no settlement amount, no verdict and no claim count. Where no such figure appears, the correct treatment is to say so, as this analysis does, rather than to infer one from the size of the recall or from comparable matters. Figures from other recalls, other drugs or other firms are not transferable.

On sourcing, the general nature of the supplied extracts is itself worth noting. Landing pages and unrelated records confirm that a database exists and is maintained; they do not confirm the contents of any particular entry. A reader who wants to verify a specific recall number should consult the entry for that number directly rather than a general results page, and should note the date on which the entry was accessed, since these records change.

Finally, a word on classification. Everything above describes a regulatory action and nothing more. No allegation in this matter has been established by a court, no verdict has been reported, and no settlement has been disclosed. Statements about the recall should be attributed to the recall record, and statements about legal consequences should await a document that actually contains them.

Sources

• U.S. Food and Drug Administration
• U.S. Food and Drug Administration
• U.S. Food and Drug Administration
• U.S. Food and Drug Administration
• Drugs@FDA: FDA-Approved Drugs
• Drugs@FDA: FDA-Approved Drugs
• Federal Register :: Agencies - Food and Drug Administration